What is Zacks Research’s Estimate for Surmodics Q2 Earnings?

Surmodics, Inc. (NASDAQ:SRDX) – Research analysts at Zacks Research cut their Q2 2026 earnings per share (EPS) estimates for Surmodics in a report released on Wednesday, May 21st. Zacks Research analyst D. Dey now expects that the company will post earnings of $0.02 per share for the quarter, down from their prior estimate of $0.04. The consensus estimate for Surmodics’ current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics’ FY2027 earnings at $0.31 EPS.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.07). Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. The firm had revenue of $28.09 million during the quarter, compared to analysts’ expectations of $32.23 million.

Several other research firms have also commented on SRDX. Wall Street Zen started coverage on shares of Surmodics in a research report on Monday, February 3rd. They issued a “hold” rating on the stock. Lake Street Capital raised Surmodics from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a research note on Friday, March 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a report on Wednesday, April 30th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $43.00.

Surmodics Stock Performance

Shares of SRDX opened at $28.70 on Friday. Surmodics has a 12-month low of $26.00 and a 12-month high of $42.44. The stock has a market cap of $410.38 million, a P/E ratio of -28.42 and a beta of 1.32. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average of $28.84 and a two-hundred day moving average of $33.89.

Institutional Investors Weigh In On Surmodics

Several hedge funds have recently modified their holdings of the company. Millennium Management LLC grew its position in shares of Surmodics by 0.4% in the fourth quarter. Millennium Management LLC now owns 120,344 shares of the company’s stock valued at $4,766,000 after purchasing an additional 509 shares during the period. Principal Financial Group Inc. lifted its position in Surmodics by 1.8% during the first quarter. Principal Financial Group Inc. now owns 36,699 shares of the company’s stock worth $1,120,000 after buying an additional 638 shares during the period. Rhumbline Advisers boosted its stake in Surmodics by 4.4% in the 4th quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock worth $802,000 after buying an additional 861 shares during the last quarter. Legal & General Group Plc boosted its stake in Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company’s stock worth $137,000 after buying an additional 880 shares during the last quarter. Finally, Salem Investment Counselors Inc. grew its holdings in Surmodics by 1.1% in the 1st quarter. Salem Investment Counselors Inc. now owns 114,950 shares of the company’s stock valued at $3,509,000 after buying an additional 1,200 shares during the period. 96.63% of the stock is owned by institutional investors and hedge funds.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).